A detailed history of Two Sigma Investments, LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Two Sigma Investments, LP holds 87,034 shares of URGN stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,034
Previous 100,422 13.33%
Holding current value
$1.03 Million
Previous $1.69 Million 34.42%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.7 - $17.92 $170,027 - $239,912
-13,388 Reduced 13.33%
87,034 $1.11 Million
Q2 2024

Aug 14, 2024

BUY
$12.72 - $19.2 $253,446 - $382,560
19,925 Added 24.75%
100,422 $1.69 Million
Q1 2024

May 15, 2024

SELL
$13.81 - $19.33 $694,062 - $971,487
-50,258 Reduced 38.44%
80,497 $1.21 Million
Q4 2023

Feb 14, 2024

BUY
$10.87 - $15.93 $114,580 - $167,918
10,541 Added 8.77%
130,755 $1.96 Million
Q3 2023

Nov 14, 2023

BUY
$8.84 - $22.64 $887,527 - $2.27 Million
100,399 Added 506.68%
120,214 $1.68 Million
Q2 2023

Aug 14, 2023

BUY
$8.75 - $14.29 $173,381 - $283,156
19,815 New
19,815 $205,000
Q2 2021

Aug 16, 2021

SELL
$15.2 - $20.94 $300,960 - $414,612
-19,800 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$17.99 - $26.96 $356,201 - $533,808
19,800 New
19,800 $386,000
Q4 2018

Feb 14, 2019

SELL
$38.35 - $50.39 $228,335 - $300,022
-5,954 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$41.65 - $51.7 $247,984 - $307,821
5,954 New
5,954 $281,000
Q2 2018

Aug 14, 2018

BUY
$48.35 - $65.33 $724,089 - $978,382
14,976 New
14,976 $745,000
Q1 2018

May 15, 2018

SELL
$38.64 - $57.54 $287,327 - $427,867
-7,436 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$27.28 - $43.26 $202,854 - $321,681
7,436
7,436 $277,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $270M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.